Medtronic Closes SPR Therapeutics Deal, Adds Peripheral Nerve Stimulation to Neuromodulation Unit
What happened
Medtronic plc completed the acquisition of SPR Therapeutics, a company focused on peripheral nerve stimulation technology for pain management. SPR Therapeutics developed the SPRINT Peripheral Nerve Stimulation System, a non-surgical, non-opioid approach to treating chronic and acute pain. Financial terms of the deal were not disclosed in the announcement. The addition of SPR Therapeutics is intended to broaden Medtronic's existing pain intervention segment within its neuromodulation unit.
The QL Read
QuantLogix composite for MDT reads 52/100, with shares at $81.67, down 0.39% on the session. The next neuromodulation segment revenue print will be the first window into any SPR-related contribution; absent that, the composite remains at a midline reading.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.